Focusing on enthesitis which is characteristic of PsA, Araujo et al. reported that ustekinumab, an anti-IL-12/IL-23p40 antibody, was superior to TNF-α inhibitors in the clearance of enthesitis [38], which underscores the importance of IL-23 in enthesitis. The gene discussed is IL23A; the disease is enthesitis.